Dr. David H. Henry

1. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia.

Herbert Aaron Eradat, et al., Abstract TPS7127

2. Independent evaluation of ibrutinib efficacy 3 years postinitiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease.

Susan Mary O’Brien, et al., Abstract 7014

3. Randomized comparison of ibrutinib vs. ofatumumab in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.

John C. Byrd, Abstract LBA7008

4. Efficacy and safety of imatinib in chronic myeloid leukemia over 10 years.

Rüdiger Hehlmann, Abstract 7021

5. Chronic myelomonocytic leukemia: Next-generation sequencing in 30 treatment-naive cases.

Priyanka Priyanka, et al., Abstract 7051

Dr. Henry is with the department of medicine at the University of Pennsylvania, Philadelphia. He is a member of the medical staff at Pennsylvania Hospital in the division of hematology/oncology and is vice chairman of its department of medicine, and editor in chief of the Journal of Community and Supportive Oncology.

1. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia.

Herbert Aaron Eradat, et al., Abstract TPS7127

2. Independent evaluation of ibrutinib efficacy 3 years postinitiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease.

Susan Mary O’Brien, et al., Abstract 7014

3. Randomized comparison of ibrutinib vs. ofatumumab in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.

John C. Byrd, Abstract LBA7008

4. Efficacy and safety of imatinib in chronic myeloid leukemia over 10 years.

Rüdiger Hehlmann, Abstract 7021

5. Chronic myelomonocytic leukemia: Next-generation sequencing in 30 treatment-naive cases.

Priyanka Priyanka, et al., Abstract 7051

Dr. Henry is with the department of medicine at the University of Pennsylvania, Philadelphia. He is a member of the medical staff at Pennsylvania Hospital in the division of hematology/oncology and is vice chairman of its department of medicine, and editor in chief of the Journal of Community and Supportive Oncology.

1. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia.

Herbert Aaron Eradat, et al., Abstract TPS7127

2. Independent evaluation of ibrutinib efficacy 3 years postinitiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease.

Susan Mary O’Brien, et al., Abstract 7014

3. Randomized comparison of ibrutinib vs. ofatumumab in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.

John C. Byrd, Abstract LBA7008

4. Efficacy and safety of imatinib in chronic myeloid leukemia over 10 years.

Rüdiger Hehlmann, Abstract 7021

5. Chronic myelomonocytic leukemia: Next-generation sequencing in 30 treatment-naive cases.

Priyanka Priyanka, et al., Abstract 7051

Dr. Henry is with the department of medicine at the University of Pennsylvania, Philadelphia. He is a member of the medical staff at Pennsylvania Hospital in the division of hematology/oncology and is vice chairman of its department of medicine, and editor in chief of the Journal of Community and Supportive Oncology.